Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan

SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
May 23, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study

SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases...
May 10, 2023 16:05 ET | Source: BioCardia, Inc.

BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
May 09, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
May 03, 2023 20:00 ET | Source: BioCardia, Inc.

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
April 28, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
April 04, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 29, 2023 08:15 ET | Source: BioCardia, Inc.

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 16, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
March 06, 2023 07:00 ET | Source: BioCardia, Inc.

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years Results Suggest CardiAMP Cell Therapy May Have Ability to Restore and Maintain Heart...